CLAYTON RAE, GASTON P, HOWIE CR. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. J Bone Joint Surg Br. 2010;92-B(3):468-468. doi:10.1302/0301-620X.92B3.24657
CLAYTON, R. A. E., et al. “Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement.”
The Journal of Bone & Joint Surgery British Volume, vol. 92-B, no. 3, 2010, pp. 468-468.,
https://doi.org/10.1302/0301-620X.92B3.24657
CLAYTON, R. A. E., GASTON, P., & HOWIE, C. R. (2010). Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement.
The Journal of Bone & Joint Surgery British Volume,
92-B(3), 468-468.
https://doi.org/10.1302/0301-620X.92B3.24657
CLAYTON, R. A. E., GASTON, P. and HOWIE, C. R. (2010) “Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement.”
The Journal of Bone & Joint Surgery British Volume, 92-B(3), pp. 468-468. Available at:
https://doi.org/10.1302/0301-620X.92B3.24657
CLAYTON, R. A. E., P. GASTON, and C. R. HOWIE. “Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement.”
The Journal of Bone & Joint Surgery British Volume 92-B, no. 3 (2010): 468-468.
https://doi.org/10.1302/0301-620X.92B3.24657
CLAYTON RAE, GASTON P, HOWIE CR. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. J Bone Joint Surg Br. 2010 Mar 1;92-B(3):468-468.
https://doi.org/10.1302/0301-620X.92B3.24657